rs773501953
Variant names:
Variant summary
Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS2
The NM_021098.3(CACNA1H):c.1623C>T(p.Pro541Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000156 in 1,540,674 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00012 ( 0 hom., cov: 34)
Exomes 𝑓: 0.00016 ( 0 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.43
Publications
1 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 16-1202073-C-T is Benign according to our data. Variant chr16-1202073-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 529623.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.43 with no splicing effect.
BS2
High AC in GnomAd4 at 18 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
CACNA1H | ENST00000569107.6 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 34 | 1 | ENSP00000454990.2 | |||
CACNA1H | ENST00000711493.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 34 | ENSP00000518778.1 | ||||
CACNA1H | ENST00000565831.7 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 34 | 1 | ENSP00000455840.1 | |||
CACNA1H | ENST00000711450.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 35 | ENSP00000518762.1 | ||||
CACNA1H | ENST00000564231.6 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 35 | 1 | ENSP00000457555.2 | |||
CACNA1H | ENST00000638323.1 | c.1584C>T | p.Pro528Pro | synonymous_variant | Exon 9 of 35 | 5 | ENSP00000492267.1 | |||
CACNA1H | ENST00000562079.6 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 34 | 1 | ENSP00000454581.2 | |||
CACNA1H | ENST00000711438.1 | c.1584C>T | p.Pro528Pro | synonymous_variant | Exon 9 of 34 | ENSP00000518754.1 | ||||
CACNA1H | ENST00000711482.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 36 | ENSP00000518771.1 | ||||
CACNA1H | ENST00000711485.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 35 | ENSP00000518774.1 | ||||
CACNA1H | ENST00000711455.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 36 | ENSP00000518768.1 | ||||
CACNA1H | ENST00000711483.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 35 | ENSP00000518772.1 | ||||
CACNA1H | ENST00000711456.1 | c.1623C>T | p.Pro541Pro | synonymous_variant | Exon 9 of 34 | ENSP00000518769.1 | ||||
CACNA1H | ENST00000621827.2 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 37 | 6 | ENSP00000518766.1 | ||||
CACNA1H | ENST00000637236.3 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 34 | 5 | ENSP00000492650.2 | ||||
CACNA1H | ENST00000639478.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000711442.1 | n.*1070C>T | non_coding_transcript_exon_variant | Exon 8 of 34 | ENSP00000518758.1 | |||||
CACNA1H | ENST00000711448.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 36 | ENSP00000518760.1 | |||||
CACNA1H | ENST00000711449.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 35 | ENSP00000518761.1 | |||||
CACNA1H | ENST00000711451.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 36 | ENSP00000518763.1 | |||||
CACNA1H | ENST00000711452.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 36 | ENSP00000518764.1 | |||||
CACNA1H | ENST00000711453.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 36 | ENSP00000518765.1 | |||||
CACNA1H | ENST00000711484.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 35 | ENSP00000518773.1 | |||||
CACNA1H | ENST00000711486.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 37 | ENSP00000518775.1 | |||||
CACNA1H | ENST00000711487.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 36 | ENSP00000518776.1 | |||||
CACNA1H | ENST00000711488.1 | n.1623C>T | non_coding_transcript_exon_variant | Exon 9 of 35 | ENSP00000518777.1 | |||||
CACNA1H | ENST00000711442.1 | n.*1070C>T | 3_prime_UTR_variant | Exon 8 of 34 | ENSP00000518758.1 | |||||
CACNA1H | ENST00000640028.1 | n.1385+238C>T | intron_variant | Intron 9 of 34 | 5 | ENSP00000491488.1 |
Frequencies
GnomAD3 genomes AF: 0.000118 AC: 18AN: 152222Hom.: 0 Cov.: 34 show subpopulations
GnomAD3 genomes
AF:
AC:
18
AN:
152222
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000119 AC: 16AN: 134214 AF XY: 0.000123 show subpopulations
GnomAD2 exomes
AF:
AC:
16
AN:
134214
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000161 AC: 223AN: 1388452Hom.: 0 Cov.: 36 AF XY: 0.000150 AC XY: 103AN XY: 684630 show subpopulations
GnomAD4 exome
AF:
AC:
223
AN:
1388452
Hom.:
Cov.:
36
AF XY:
AC XY:
103
AN XY:
684630
show subpopulations
African (AFR)
AF:
AC:
0
AN:
31490
American (AMR)
AF:
AC:
8
AN:
35558
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
25072
East Asian (EAS)
AF:
AC:
0
AN:
35614
South Asian (SAS)
AF:
AC:
1
AN:
79088
European-Finnish (FIN)
AF:
AC:
0
AN:
41276
Middle Eastern (MID)
AF:
AC:
0
AN:
5678
European-Non Finnish (NFE)
AF:
AC:
207
AN:
1076948
Other (OTH)
AF:
AC:
7
AN:
57728
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
17
33
50
66
83
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.000118 AC: 18AN: 152222Hom.: 0 Cov.: 34 AF XY: 0.0000941 AC XY: 7AN XY: 74368 show subpopulations
GnomAD4 genome
AF:
AC:
18
AN:
152222
Hom.:
Cov.:
34
AF XY:
AC XY:
7
AN XY:
74368
show subpopulations
African (AFR)
AF:
AC:
2
AN:
41464
American (AMR)
AF:
AC:
1
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5194
South Asian (SAS)
AF:
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
AC:
0
AN:
314
European-Non Finnish (NFE)
AF:
AC:
15
AN:
68026
Other (OTH)
AF:
AC:
0
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.519
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Epilepsy, childhood absence, susceptibility to, 6;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jul 20, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Dec 09, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.